BRPI0506843A - composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto - Google Patents

composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto

Info

Publication number
BRPI0506843A
BRPI0506843A BRPI0506843-6A BRPI0506843A BRPI0506843A BR PI0506843 A BRPI0506843 A BR PI0506843A BR PI0506843 A BRPI0506843 A BR PI0506843A BR PI0506843 A BRPI0506843 A BR PI0506843A
Authority
BR
Brazil
Prior art keywords
compound
preparing
pharmaceutical composition
usable
formula
Prior art date
Application number
BRPI0506843-6A
Other languages
English (en)
Inventor
David Ian Carter Scopes
Michael Glen Orchard
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BRPI0506843A publication Critical patent/BRPI0506843A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

COMPOSTO, COMPOSIçãO FARMACêUTICA, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO, E USO DE UM COMPOSTO Composto de fórmula (I): em que R representa vários grupos substituintes são utilizáveis como inibidores de glucosilceramida sintase.
BRPI0506843-6A 2004-01-14 2005-01-11 composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto BRPI0506843A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0400812.4A GB0400812D0 (en) 2004-01-14 2004-01-14 Novel compounds
PCT/GB2005/000071 WO2005068426A1 (en) 2004-01-14 2005-01-11 Piperidine derivatives as gcs inhibitors

Publications (1)

Publication Number Publication Date
BRPI0506843A true BRPI0506843A (pt) 2007-06-12

Family

ID=31726188

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506843-6A BRPI0506843A (pt) 2004-01-14 2005-01-11 composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto

Country Status (10)

Country Link
US (1) US20080234324A1 (pt)
EP (1) EP1709000A1 (pt)
JP (1) JP2007517846A (pt)
CN (1) CN1910150A (pt)
AU (1) AU2005205221A1 (pt)
BR (1) BRPI0506843A (pt)
CA (1) CA2552550A1 (pt)
GB (1) GB0400812D0 (pt)
IL (1) IL176823A0 (pt)
WO (1) WO2005068426A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
JP4585851B2 (ja) 2002-07-17 2010-11-24 アクテリオン ファーマシューティカルズ リミテッド グルコシルセラミドシンターゼの阻害剤としてのピペリジントリオール誘導体
EP1534676B1 (en) 2002-07-17 2012-09-12 Actelion Pharmaceuticals Ltd. Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
GB0313678D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
CA2586761A1 (en) 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
EP2923699B1 (en) 2006-05-09 2018-06-20 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
EP2594564B1 (en) 2007-05-31 2016-09-28 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
MX337396B (es) 2007-10-05 2016-03-02 Genzyme Corp Metodo para el tratamiento de enfermedades del riñon poliquisticas con derivados de ceramica.
WO2010014554A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP3078373A1 (en) 2008-10-03 2016-10-12 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitor
WO2010091164A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Inhibitors of glucosylceramide synthase
WO2010091104A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Glucosylceramide synthase inhibitors
CA2830540C (en) 2011-03-18 2021-04-27 Genzyme Corporation Glucosylceramide synthase inhibitors
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
CN108658970A (zh) 2013-03-15 2018-10-16 建新公司 制备葡萄糖基神经酰胺合酶抑制剂的方法
EP3046920B1 (en) 2013-09-20 2021-08-04 BioMarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
FR3011468B1 (fr) * 2013-10-04 2015-12-04 Inventiva Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose
HUE040220T2 (hu) 2013-10-29 2019-02-28 Biomarin Pharm Inc N-(1-hidroxi-3-(pirrolidinil)propan-2-il)pirrolidin-3-karboxamid származékok mint glükozilceramid-szintáz inhibitorok
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
EP3215509B1 (en) 2014-11-06 2020-02-26 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
CN107001379B (zh) 2014-11-06 2022-11-01 Bial研发投资股份有限公司 取代的吡唑并[1,5-a]嘧啶以及它们在治疗医学障碍中的用途
US10227312B2 (en) 2015-03-11 2019-03-12 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
BR112018070586A8 (pt) 2016-04-06 2023-04-11 Lysosomal Therapeutics Inc Compostos de pirazol[1,5-a]pirimidinil carboxamida e seu uso no tratamento de distúrbios médicos
CA3020310A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US10787454B2 (en) 2016-04-06 2020-09-29 BIAL—BioTech Investments, Inc. Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3452045A1 (en) * 2016-05-04 2019-03-13 Lysosomal Therapeutics Inc. Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
EP3452481A4 (en) 2016-05-05 2020-02-26 Lysosomal Therapeutics Inc. IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS
US11345698B2 (en) 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
CN113645969A (zh) 2019-02-04 2021-11-12 建新公司 用于治疗与溶酶体贮积症相关的症状和病症的方法
CA3166777A1 (en) 2020-02-03 2021-08-12 Nigel Patrick Somerville CRAWFORD Methods for treating neurological symptoms associated with lysosomal storage diseases
FR3109523B1 (fr) * 2020-04-23 2023-11-17 Univ Grenoble Alpes Nouveaux composés chaperons pharmacologiques de l’alpha-glucosidase acide humaine et leur utilisation thérapeutique
WO2021221953A1 (en) 2020-04-28 2021-11-04 The Regents Of The University Of Michigan Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same
AU2021311131A1 (en) 2020-07-24 2023-03-23 Genzyme Corporation Pharmaceutical compositions comprising venglustat

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0536402A4 (en) * 1990-06-29 1993-05-12 Nippon Shinyaku Company, Limited Piperidine derivative
AU753336B2 (en) * 1997-11-10 2002-10-17 G.D. Searle & Co. Use of alkylated iminosugars to treat multidrug resistance
GB0100889D0 (en) * 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds

Also Published As

Publication number Publication date
GB0400812D0 (en) 2004-02-18
AU2005205221A1 (en) 2005-07-28
US20080234324A1 (en) 2008-09-25
EP1709000A1 (en) 2006-10-11
WO2005068426A1 (en) 2005-07-28
CA2552550A1 (en) 2005-07-28
IL176823A0 (en) 2006-10-31
JP2007517846A (ja) 2007-07-05
CN1910150A (zh) 2007-02-07

Similar Documents

Publication Publication Date Title
BRPI0506843A (pt) composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
BRPI0206433B8 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0613429A2 (pt) inibidores de histona desacetilase
BRPI0720525B8 (pt) inibidores de mapk/erk quinase
ECSP11011183A (es) Compuestos orgánicos
ECSP11011184A (es) Compuestos orgánicos
ECSP077271A (es) Derivados de pirimidina
BRPI0514125A (pt) piridinas condensadas como inibidores de cinase
UY29479A1 (es) Inhibidores de adn-pk
ECSP077259A (es) Derivados de pirimidina
BRPI0510410A (pt) compostos orgánicos
DOP2010000178A (es) Peptidil nitrilos como inhibidores de dipeptidil peptidasa i
UY31069A1 (es) Nuevos derivados de imidazoquinola, composiciones conteniendolos, proceso de preparacion y aplicaciones
BRPI0508102A (pt) inibidores de caspase e usos dos mesmos
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
CR11618A (es) Inhibidores macrocíclicos de serina proteasa
BRPI0418639B8 (pt) compostos inibidores de dipeptidil peptidase, assim como composição farmacêutica contendo os mesmos
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
BRPI0518509A2 (pt) pirrolopirazàis, inibidores de cinase potentes
CO6541643A2 (es) Derivados de imidazopirina como inhibidores de jak
UY30748A1 (es) Compuesto0s novedosos
BRPI0510412A (pt) compostos orgánicos
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5
UY29607A1 (es) Compuestos quimicos
GT200800251A (es) Nitrilos espirociclicos como inhibidores de proteasa

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.